June Sherie Almenoff - Net Worth and Insider Trading
June Sherie Almenoff Net Worth
The estimated net worth of June Sherie Almenoff is at least $1,761 dollars as of 2024-09-20. June Sherie Almenoff is the Director of Brainstorm Cell Therapeutics Inc and owns about 7,175 shares of Brainstorm Cell Therapeutics Inc (BCLI) stock worth over $1,761. June Sherie Almenoff is also the COO and Chief Medical Officer of 9 Meters Biopharma Inc and owns about 70 shares of 9 Meters Biopharma Inc (NMTRQ) stock worth over $0. Details can be seen in June Sherie Almenoff's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that June Sherie Almenoff has not made any transactions after 2019-01-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of June Sherie Almenoff
June Sherie Almenoff Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, June Sherie Almenoff owns 5 companies in total, including Brainstorm Cell Therapeutics Inc (BCLI) , 9 Meters Biopharma Inc (NMTRQ) , and NeuBase Therapeutics Inc (NBSE) among others .
Click here to see the complete history of June Sherie Almenoff’s form 4 insider trades.
Insider Ownership Summary of June Sherie Almenoff
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BCLI | Brainstorm Cell Therapeutics Inc | 2019-12-12 | director |
| NMTRQ | 9 Meters Biopharma Inc | 2018-08-24 | COO and Chief Medical Officer |
| NBSE | NeuBase Therapeutics Inc | 2013-06-13 | director |
 | | 2021-06-10 | director |
| | 2021-12-31 | director |
June Sherie Almenoff Latest Holdings Summary
June Sherie Almenoff currently owns a total of 2 stocks. Among these stocks, June Sherie Almenoff owns 7,175 shares of Brainstorm Cell Therapeutics Inc (BCLI) as of January 4, 2019, with a value of $1,761 and a weighting of 100%. June Sherie Almenoff also owns 70 shares of 9 Meters Biopharma Inc (NMTRQ) as of August 24, 2018, with a value of $0 and a weighting of 0%.
Latest Holdings of June Sherie Almenoff
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BCLI | Brainstorm Cell Therapeutics Inc | 2019-01-04 | 7,175 | 0.25 | 1,761 |
| NMTRQ | 9 Meters Biopharma Inc | 2018-08-24 | 70 | 0.00 | 0 |
Holding Weightings of June Sherie Almenoff
June Sherie Almenoff Form 4 Trading Tracker
According to the SEC Form 4 filings, June Sherie Almenoff has made a total of 0 transactions in Brainstorm Cell Therapeutics Inc (BCLI) over the past 5 years. The most-recent trade in Brainstorm Cell Therapeutics Inc is the acquisition of 1,475 shares on January 4, 2019, which cost June Sherie Almenoff around $5,000.
According to the SEC Form 4 filings, June Sherie Almenoff has made a total of 0 transactions in 9 Meters Biopharma Inc (NMTRQ) over the past 5 years. The most-recent trade in 9 Meters Biopharma Inc is the acquisition of 70 shares on August 24, 2018, which cost June Sherie Almenoff around $6,888.
Insider Trading History of June Sherie Almenoff
- 1
June Sherie Almenoff Trading Performance
GuruFocus tracks the stock performance after each of June Sherie Almenoff's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by June Sherie Almenoff is 3.41%. GuruFocus also compares June Sherie Almenoff's trading performance to market benchmark return within the same time period. The performance of stocks bought by June Sherie Almenoff within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how June Sherie Almenoff's insider trading performs compared to the benchmark.
Performance of June Sherie Almenoff
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.71 | | | | | |
| Relative Return to S&P 500(%) | 18.76 | | | | | |
June Sherie Almenoff Ownership Network
June Sherie Almenoff Owned Company Details
What does Brainstorm Cell Therapeutics Inc do?
Who are the key executives at Brainstorm Cell Therapeutics Inc?
June Sherie Almenoff is the director of Brainstorm Cell Therapeutics Inc. Other key executives at Brainstorm Cell Therapeutics Inc include Chief Executive Officer Chaim Lebovits , EVP & Head Global Clin Research Stacy Lindborg , and Chief Medical Officer Kirk Taylor .
Brainstorm Cell Therapeutics Inc (BCLI) Insider Trades Summary
Over the past 18 months, June Sherie Almenoff made no insider transaction in Brainstorm Cell Therapeutics Inc (BCLI). Other recent insider transactions involving Brainstorm Cell Therapeutics Inc (BCLI) include a net purchase of 566,372 shares made by Chaim Lebovits , a net sale of 63,000 shares made by , and a net purchase of 11,500 shares made by Stacy Lindborg .
In summary, during the past 3 months, insiders sold 63,000 shares of Brainstorm Cell Therapeutics Inc (BCLI) in total and bought 0 shares, with a net sale of 63,000 shares. During the past 18 months, 63,000 shares of Brainstorm Cell Therapeutics Inc (BCLI) were sold and 577,872 shares were bought by its insiders, resulting in a net purchase of 514,872 shares.
Brainstorm Cell Therapeutics Inc (BCLI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Brainstorm Cell Therapeutics Inc Insider Transactions
June Sherie Almenoff Mailing Address
Above is the net worth, insider trading, and ownership report for June Sherie Almenoff. You might contact June Sherie Almenoff via mailing address: C/o Brainstorm Cell Therapeutics Inc., 1325 Avenue Of Americas 28th Floor, New York Ny 10019.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
